Icure Pharm Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 288

Employees

  • Stock Symbol
  • 175250

Stock Symbol

  • Share Price
  • $1.57
  • (As of Friday Closing)

Icure Pharm General Information

Description

Icure Pharmaceutical Inc operates as a biopharmaceutical company engages in the development and commercialization of novel transdermal drug delivery formulation. It also developed and commercialized various patches and hydrogels for the treatment of rheumatic arthritis pain, nicotine replacement therapy, medicated wound dressings, skin care, and dental care. The products pipeline is also aimed at the development of prescription drugs to diseases of the central nervous system, asthma, and pain.

Contact Information

Website
www.icure.co.kr
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
KRX
Primary Office
  • 10 Bongeunsa-Ro 104-Gil, Gangnam-Gu
  • Seoul, Seocho-gu 06170
  • South Korea
+82 00-0000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Icure Pharm Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.57 $1.58 $1.31 - $3.83 $58.8M 37.4M 248K -$1.03

Icure Pharm Financials Summary

In Thousands,
USD 		TTM 30-Sep-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 104,675 119,398 331,130 472,059
Revenue 45,232 45,946 56,122 76,348
EBITDA (16,137) (22,370) (23,211) (1,940)
Net Income (26,330) (32,324) (33,321) (10,684)
Total Assets 133,017 177,464 181,046 178,885
Total Debt 54,310 67,220 60,911 53,897
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Icure Pharm Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Icure Pharm‘s full profile, request access.

Request a free trial

Icure Pharm Patents

  • 34

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 23

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Icure Pharm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3415141-A1 Ultraviolet-hardening hydrogel resin and hydrogel for transdermal administration, and cataplasm agent containing same Pending 11-Feb-2016 000000000
US-20190046463-A1 Ultraviolet-hardening hydrogel resin and hydrogel for transdermal administration, and cataplasm agent containing same Active 11-Feb-2016 000000000
US-11382868-B2 Transdermal uv-curable hydrogel resin, hydrogel curing the same and cataplasm containing the same Active 11-Feb-2016 000000000 00
JP-2020158514-A Cataplasm agent containing ultraviolet-curable hydrogel for transdermal administration Active 11-Feb-2016 000000000 0
EP-3415141-A4 Ultraviolet-hardening hydrogel resin and hydrogel for transdermal administration, and cataplasm agent containing same Pending 11-Feb-2016 A61K9/703 0
To view Icure Pharm’s complete patent history, request access »

Icure Pharm Executive Team (2)

Name Title Board Seat Contact Info
YoungKweon Choi Ph.D Founder, CTO & Chief Executive Officer
You’re viewing 1 of 2 executive team members. Get the full list »

Icure Pharm Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial